33410 - Sr Biopharmaceutical Rep

Orion Group Life Sciences are looking for a Senior Biopharmaceutical Rep on behalf of our Multinational Pharmaceutical/Biotechnology client located in Uxbridge. Initial 6-month contract, with possibility of extension and for the right candidate a possibility to go permanent.

What you will do

Our client will be launching a biosimilar within the Gastroenterology space and in 2 Phases. The first phase will be in July 2024 and the second phase in September 2024. There will be a tender and then a contract put in place, though we don't know the content or outcome of this at this stage. The biosimilar will be promoted by the current Inflammation sales force team of 11 Regional Account Managers who currently also promote Amgevita (Adalimumab biosimilar) and Otezla (Apremilast). Following analysis when preparing the 'Go to Market Model' for the launch biosimilar it is evident that in order to achieve all KPIs related to activity and sales and for a successful launch further capacity is needed. The launch phase will move fast with biosimilar uptake being steep during the first 6 months post launch. The increased capacity with 2 contingency workers will ensure all relevant stakeholders are reached during the launch phase and the Inflammation current portfolio will also reach KPIs set for each Brand. There will be other competitor biosimilars coming to the market at the same time.

We are adding 2 FTE Contingency workers to support the reach to key stakeholders during the launch phase of a new biosimilar. This would be on an initial contract period of 6 months. Promoting the biosimilar to defined priority accounts, achieving formulary status and supporting a seamless transition from originator to biosimilar for new and existing patients.

Responsibilities:

• Product to be promoted: Biosimilar Ustekinumab.
• To promote the biosimilar to key accounts, where it is pivotal to reach key stakeholders and ensure a seamless transition. This will include supporting the transition of both new and existing patients:

• Exact account list and parameters tbc.
• Account list and customers to remain flexible to account for dynamics related to the tender environment and RAM capacity post launch.
• Accounts will likely overlap with current RAM territory boundaries.
• Any leads related to Amgevita and Otezla are to be forwarded to the relevant RAM.

• To promote biosimilar Ustekinumab using appropriate resources, insights and key messages which will include both product attributes and value to the system.
• To provide training to the MDT within Gastroenterology Depts and Dermatology Departments on the delivery device.
• Collect email permissions/consents during calls.
• Customer groups to be engaged with will include the Gastroenterology and Dermatology MDT, Key Pharmacists (Homecare, Biologics, High Cost, Formulary, Chief and Medicines Optimization Stakeholders). The MDT will include Clinicians and Nurse Specialists.
• To provide timely insights cross functionally at team meetings and through appropriate channels. Add insights to developed National Tracker and share best practice cross functionally:

• Examples of insights may be recent formulary/biosimilar choice decisions and any competitor intelligence that will drive tactics Nationally.

• Stakeholder mapping - to identify and access key stakeholders involved in biosimilar decision making and biosimilar implementation at account level, including clinical and payor stakeholders.
• To reach priority accounts allocated with pace and understand the formulary process steps, access those stakeholders involved to achieve formulary status.
• Meet with key stakeholders to understand the implementation plan related to Biosimilar Ustekinumab, promote using appropriate resources and use the cross functional team where needed to overcome any barriers or obstacles.
• Ensure priority accounts have MDT meetings set up for September (Gastro, Derm, Pharmacy).
• Support accounts to have a seamless transition overcoming issues and barriers and using peer to peer influence - for both new and existing patients on Stelara.

Expectations

• To complete all necessary LMS training.
• Completion of Code of Conduct Training.
• Completion of Antibribery training.
• Completion of Privacy and Data Protection Training.
• ABPI qualification.
• SmPC training.
• Adverse event reporting.
• Actioning of Med info requests.
• Experience as a Sales Rep in a specialist / secondary care market.
• Demonstrate communication with impact.
• Entrepreneurial self-starter piece - there is a launch piece, we can't spoon feed the CW, we will want them to be pro-active and seek customer opportunities and drive results.
• Driving License.
• Access to their own car.

If you would like to have a confidential conversation regarding this opportunity please reach out to Tim Browaeys, tim.browaeys@orioneng.com or contact Tim on 0044 7593448607

#opportunity #multinational #pharmaceutical #biotechnology #senior #biopharmaceutical #representative #sales #biosimilar #inflammation #secondcaremarket

Our role in supporting diversity and inclusion
As an international workforce business, we are committed to sourcing personnel that reflects the diversity and values of our client base but also that of Orion Group. We welcome the wide range of experiences and viewpoints that potential workers bring to our business and our clients, including those based on nationality, gender, culture, educational and professional backgrounds, race, ethnicity, sexual orientation, gender identity and expression, disability, and age differences, job classification and religion. In our inclusive workplace, regardless of your employment status as staff or contract, everyone is assured the right of equitable, fair and respectful treatment.